FDA OKs Immune Globulin Cuvitru for Primary Immunodeficiency FDA OKs Immune Globulin Cuvitru for Primary Immunodeficiency

Approval of immune globulin subcutaneous 20% solution follows positive data on efficacy and safety, as well as infusion time and number of injections sites.FDA Approvals
Source: Medscape Allergy Headlines - Category: Allergy & Immunology Tags: Allergy & Clinical Immunology News Alert Source Type: news

Related Links:

Publication date: March 2019Source: The Journal of Allergy and Clinical Immunology: In Practice, Volume 7, Issue 3Author(s): Evans R. Fernández Pérez, Maya Hunter, Rohit K. Katial
Source: The Journal of Allergy and Clinical Immunology: In Practice - Category: Allergy & Immunology Source Type: research
Publication date: March 2019Source: The Journal of Allergy and Clinical Immunology: In Practice, Volume 7, Issue 3Author(s): John B. Ziegler, Mark Ballow
Source: The Journal of Allergy and Clinical Immunology: In Practice - Category: Allergy & Immunology Source Type: research
Publication date: March 2019Source: The Journal of Allergy and Clinical Immunology: In Practice, Volume 7, Issue 3Author(s):
Source: The Journal of Allergy and Clinical Immunology: In Practice - Category: Allergy & Immunology Source Type: research
Publication date: March 2019Source: The Journal of Allergy and Clinical Immunology: In Practice, Volume 7, Issue 3Author(s): Richard MitchellHematopoietic stem cell transplantation (HSCT) can provide definitive therapy for patients with primary immunodeficiency disease (PIDD). Modern HSCT techniques and supportive care have significantly improved outcomes for patients with PIDD. This review examines current HSCT practice for PIDD other than severe combined immunodeficiency, and explores indications, risks, and long-term outcomes for this group of challenging diseases.
Source: The Journal of Allergy and Clinical Immunology: In Practice - Category: Allergy & Immunology Source Type: research
Publication date: March 2019Source: The Journal of Allergy and Clinical Immunology: In Practice, Volume 7, Issue 3Author(s):
Source: The Journal of Allergy and Clinical Immunology: In Practice - Category: Allergy & Immunology Source Type: research
Publication date: March 2019Source: The Journal of Allergy and Clinical Immunology: In Practice, Volume 7, Issue 3Author(s): Jennifer W. Leiding, Lisa R. ForbesAdvances in understanding the mechanism, immunobiology, and pathophysiology of primary immunodeficiency diseases have created opportunities for the use of precision medicines for the treatment of disease-related manifestations. Modulation of the immune system to treat autoimmunity began with the use of intravenous immunoglobulin, improved with the development of monoclonal antibodies, and has now become standard in certain diseases with mechanistic-based targets tha...
Source: The Journal of Allergy and Clinical Immunology: In Practice - Category: Allergy & Immunology Source Type: research
This study delineates the mitochondrial defects in DOCK2-deficient T cells contributing to the T cell lymphopenia characteristic of this primary immunodeficiency.
Source: Journal of Allergy and Clinical Immunology - Category: Allergy & Immunology Authors: Source Type: research
ConclusionAvailable evidence suggests that PID patients have a lower HRQL than healthy individuals and patients with other chronic conditions, including diabetes mellitus and juvenile idiopathic arthritis. No disease-specific instruments are available for children and few options are available for adults. This finding highlights the need for developing PID-specific instruments which would allow for a more sensitive evaluation of PID impact on patient health and psychological wellbeing, school/work and social activities.
Source: The Journal of Allergy and Clinical Immunology: In Practice - Category: Allergy & Immunology Source Type: research
Aggressive mature B-cell LPD can occur in WAS as in XLT pediatric and adult patients. Immunochemotherapy is applicable to all WAS/XLT patients, while transplantation still remains controversial for adult patients.
Source: Journal of Allergy and Clinical Immunology - Category: Allergy & Immunology Authors: Source Type: research
Abstract The primary immunodeficiency diseases (PIDs) include many genetic disorders that affect different components of the innate and adaptive responses. The number of distinct genetic PIDs has increased exponentially with improved methods of detection and advanced laboratory methodology. Patients with PIDs have an increased susceptibility to infectious diseases and non-infectious complications including allergies, malignancies and autoimmune diseases (ADs), the latter being the first manifestation of PIDs in several cases. There are two types of PIDS. Monogenic immunodeficiencies due to mutations in genes invol...
Source: Journal of Autoimmunity - Category: Allergy & Immunology Authors: Tags: J Autoimmun Source Type: research
More News: Allergy | Allergy & Immunology | Gammagard Liquid | Primary Immunodeficiency Disease | Privigen